Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.

Scientific reports - 22 Feb 2022

Amintas Samuel, Fernandez Benjamin, Chauvet Alexandre, Chiche Laurence, Laurent Christophe, Belleannée Geneviève, Marty Marion, Buscail Etienne, Dabernat Sandrine

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) patients eligible for curative surgery undergo unpredictable disease relapse. Even patients with a good pathological response after neoadjuvant treatment (NAT) remain susceptible to recurrent PDAC. Molecular analysis of R0 margins may identify patients with a worse prognosis. The molecular status of mutant KRAS (exon 2, codon 12/13) was analysed retrospectively by digital...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Carcinoma, Pancreatic Ductal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoadjuvant Therapy

Share to Neoplasm Recurrence, Local

Share to Pancreatic Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 35194118
DOI: 10.1038/s41598-022-07004-x
PMCID: PMC8864048

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrence.PMID 35194118Read ↗

KRAS gene mutation quantification in the resection or venous margins of pancreatic ductal adenocarcinoma is not predictive of disease recurrenceSemantic proximity Read ↗

KRAS mutational analysis in ductal adenocarcinoma of the pancreas and its clinical significance.Semantic proximity Read ↗

Plasma KRAS mutations predict the early recurrence after surgical resection of pancreatic cancer.Semantic proximity Read ↗

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Predicting disease recurrence in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Resectable pancreatic head adenocarcinoma: Is R0 resection an illusion? Genetic evaluation of venous resection margin affirmed unrecognized disease.Semantic proximity Read ↗

Peritoneal Cell-Free Tumor DNA is a Biomarker of Locoregional and Peritoneal Recurrence in Resected Pancreatic Ductal Adenocarcinomas.Semantic proximity Read ↗

Mutant KRAS in Circulating Tumor DNA as a Biomarker in Localized Pancreatic Cancer Patients Treated With Neoadjuvant Chemotherapy.Semantic proximity Read ↗

Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.Semantic proximity Read ↗

Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.Semantic proximity Read ↗

KRAS variant allele frequency, but not mutation positivity, associates with survival of patients with pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.